Article Listing - Rhone-Poulenc Rorer's 3rd Qtr As Expected

FERMENTA INTO LOSS

6 April 1992

Swedish drugmaker Fermenta reported a 1.23 billion kroner ($203.4 million) loss for 1991, compared with a loss of 599 million...

STOCK MARKET COMMENTARY: NEW YORK

6 April 1992

NEW YORK: share prices moved up and down during the reporting week, first with lower car sales pushing the Dow...

US MEDICAID REBATES AND "BEST PRICES"

6 April 1992

Eliminating the "best price" provision from the US Medicaid rebate formula for the top 100 single-source and innovator multiple-source drugs...

US FDA USER FEES: "THE TIME HAS COME"

6 April 1992

People in the US Food and Drug Administration-regulated industries now recognize that the time has arrived for user fees to...

ICN HUBBER GROUP IN SPAIN

6 April 1992

The ICN Hubber Group is investing 1.7 billion pesetas ($2.2 million) in a new pharmaceutical plant near Barcelona in Spain....

ALLELIX BIOPHARMA: DOUGLAS FROOM

6 April 1992

Douglas Froom has been appointed as vice president for business development at Allelelix Biopharmaceuticals Inc, of Canada.

BAYER DIAGNOSTICS' NEW INSTRUMENT

6 April 1992

Bayer Diagnostics has launched the Ames Clinitek 200+, benchtop, semi-automated urine chemistry analyser for moderate to large volume urine testing....

US MEDICAID REBATES AND "BEST PRICES"

6 April 1992

Eliminating the "best price" provision from the US Medicaid rebate formula for the top 100 single-source and innovator multiple-source drugs...

FUTURE PRODUCTS FROM GENETICS INSTITUTE

6 April 1992

Highlighting the most prominent products and product candidates in its commercial development pipeline, Genetics Institute acknowledges that significant progress has...

LOWER SALES/PROFIT FOR BAYER ITALY

6 April 1992

In line with the group's overall international performance, Bayer Italia reports lower sales and profits in 1991. The subsidiary of...

Showing 94491-94500 of 95353 articles